Dr. François Emond completed his medical degree at Laval University in 1997 and his residency in adult neurology in 2002. After a clinical fellowship in multiple sclerosis at The Ottawa Hospital under the direction of Dr. Mark S. Freedman, he joined the neurology department of the CHU of Quebec-Hôpital de l’Enfant-Jésus. Since 2012, he has been director of the multiple sclerosis clinic at the CHU of Quebec and IRDPQ (CIUSSS Capitale-Nationale – François-Charron Centre). In addition to following several hundred patients with multiple sclerosis, he regularly participates in teaching students, externs and residents of the RUIS-Laval network.

Since 2003, Dr. Emond has been involved, as primary local investigator or co-investigator, in multiple clinical trials on the long-term treatment of multiple sclerosis.

1401, 18e Rue
Département des sciences neurologiques
Québec, Québec
Canada G1J 1Z4
+1 418-649-0252
+1 418-649-5915
francois.emond@crchudeque...

Latest news

Data not available

Grand'Maison F, Yeung M, Morrow SA, Lee L, Emond F, Ward BJ, Laneuville P, Schecter R

Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches.

Journal Article

Neural Regen Res, 13 (11), 2018.

Abstract | Links:

Traboulsee AL, Machan L, Girard JM, Raymond J, Vosoughi R, Hardy BW, Emond F, Gariepy JL, Bone JN, Siskin G, Klass D, Isserow S, Illes J, Sadovnick AD, Li DK

Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial.

Journal Article

Neurology, 91 (18), 2018.

Abstract | Links:

Grand'Maison F, Yeung M, Morrow SA, Lee L, Emond F, Ward BJ, Laneuville P, Schecter R

Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment.

Journal Article

Curr Med Res Opin, 34 (8), 2018.

Abstract | Links:

Gamache PL, Gagnon MM, Savard M, Emond F

Pulvinar sign in a case of anti-HU paraneoplastic encephalitis.

Journal Article

Neuroradiol J, 29 (6), 2016.

Abstract | Links:

Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, Morgenthau D, Lapierre Y, Émond F, Duquette P, Emond F, Feinstein A, Giacomini P, Geenen C, Jacques F, Jobin C, Larochelle C, Lee L, MacDougall A, MacLean H, Mandalfino P, Marriott J, Metz L, Morrow S, Myles ML, Oger J, Patry D, Pearson D, Smyth P, Pohl D, Traboulsee A, Tremlett H, Venkateswaran S

Treatment optimization in MS: Canadian MS Working Group updated recommendations.

Journal Article

Can J Neurol Sci, 40 (3), 2013.

Abstract | Links:

Dupre N, Riviere JB, Myers RH, Provencher P, Pourcher E, Emond F, Rouleau GA

LRRK2 is not a significant cause of Parkinson's disease in French-Canadians.

Journal Article

Can J Neurol Sci, 34 (3), 2007.

Abstract | Links:

Signaler des ajouts ou des modifications